(561) 214-3323

Thymosin Alpha-1

Educational Overview

Thymosin Alpha-1: What the Research Shows

Originally published 9/3/2024 · Updated 10/6/2026

Thymosin alpha-1 (also called thymalfasin or TA-1) is a peptide first identified in extracts of the thymus gland, an organ involved in the development of T-cells. It has been studied in laboratories and clinical trials for decades. This article is a general introduction to what it is, how researchers believe it works, and where the evidence stands today, including what remains unknown.

Important

  • Thymosin alpha-1 is not FDA-approved for any use in the United States.
  • In December 2024, the FDA’s Pharmacy Compounding Advisory Committee voted against adding it to the 503A bulks list[3]. See our FDA Peptide Review for the current outlook.
  • Research on this peptide is ongoing, and much of it is laboratory or small-trial work.
  • Nothing here is medical advice, a recommendation, or a promise of results.

At a Glance

What it is A 28-amino-acid peptide first isolated from thymus tissue. The version studied clinically is made synthetically.
Proposed mechanism In laboratory and animal studies, it interacts with toll-like receptors on dendritic cells, which are immune-signaling cells[1].
Human evidence Mixed. A 2025 meta-analysis of sepsis trials found a signal in pooled data, but not in the higher-quality or multicenter subgroups[2].
U.S. regulatory status Not FDA-approved. Advisory committee voted 17–4 against adding it to the 503A bulks list in December 2024[3].

Explore the Topic

Open any section below to learn more.

What is thymosin alpha-1?
▼

Thymosin alpha-1 is a small peptide, 28 amino acids long. It was originally found in extracts of the thymus, a gland that sits behind the breastbone and plays a role in the maturation of T-cells, a type of white blood cell.

The peptide studied in clinical trials is manufactured synthetically. It is sometimes called thymalfasin, and it has been researched under the brand name Zadaxin in some countries outside the United States. It is a different molecule from thymosin beta-4, which is covered in our BPC-157 vs. TB-500 article.

How do researchers think it works?
▼

Most mechanism research has used cell cultures and animals. In one widely cited study, thymosin alpha-1 triggered the maturation of dendritic cells and the release of the signaling molecule interleukin-12. That effect involved toll-like receptors and the p38 MAPK and NF-κB signaling pathways. In mice, these changes were associated with a stronger Th1-type immune response to a fungal pathogen[1].

These are findings from laboratory and animal work. They describe a proposed mechanism and do not show that the same effects occur in people or that they lead to any health benefit.

What has been studied in people?
▼

Thymosin alpha-1 has been tested in human trials in several areas, including critical illness such as sepsis, infections, and cancer settings. The best-organized recent summary is a 2025 meta-analysis of randomized trials in sepsis. It pooled 11 trials and 1,927 patients and reported lower 28-day mortality overall (odds ratio 0.73; 95% CI 0.59–0.90)[2].

The same analysis found no significant mortality difference in its higher-quality studies (OR 0.82; 95% CI 0.65–1.03) or its multicenter trials (OR 0.86; 95% CI 0.68–1.08), and its authors concluded the pooled sample was too small to draw firm conclusions[2].

What the evidence can — and can’t — tell us
▼
What has been found What is still unknown
Laboratory work describes effects on dendritic cells and cytokine signaling[1]. Whether these effects translate into meaningful outcomes in people.
Pooled sepsis trials showed a lower 28-day mortality signal[2]. The signal disappeared in higher-quality and multicenter subgroups. All included studies were from China, and publication bias was detected[2].
The FDA advisory committee reviewed the available data in 2024[3]. The committee majority found no compelling evidence of clinical effectiveness and safety for the uses reviewed[3].
Regulatory status
▼

Thymosin alpha-1 is not FDA-approved for any use. On December 4, 2024, the FDA’s Pharmacy Compounding Advisory Committee voted 17 to 4 against including thymosin alpha-1 (free base) on the 503A bulks list, and 17 to 4 against thymosin alpha-1 acetate. Members voting no cited a lack of compelling evidence of clinical effectiveness and safety for the uses reviewed[3].

Regulatory decisions can change as new data and FDA rule-making emerge. We track developments in our FDA Peptide Review.

Safety Considerations
▼
  • Not FDA-approved. Safety and effectiveness have not been established through FDA review for use in the United States.
  • Evidence limits: published trials were mostly small, and the FDA advisory committee did not find compelling evidence of safety and effectiveness for the uses reviewed[2][3].
  • Immune-active peptide: because it is studied for effects on immune signaling, anyone with an autoimmune condition, an organ transplant, or on immune-modifying medicines should discuss it with a licensed clinician before considering it.
  • “Research Use Only” and unlicensed sources carry risks of wrong contents, wrong dose, contamination, or no sterility testing.
  • Injectable products can cause injection-site reactions and, rarely, severe allergic reactions. Seek emergency care for hives, wheezing, difficulty breathing, or swelling of the face, lips, tongue, or throat.
  • Pregnancy and breastfeeding: there is no established safety data. Discuss with a licensed clinician.

Our Perspective

This section is editorial, not FDA policy. Interest in thymosin alpha-1 is understandable given decades of research, but interest is not the same as proof. If you come across it from any source, we suggest asking three questions:

  1. Which exact molecule is in it? Make sure it is thymosin alpha-1, not another thymosin.
  2. Where was it made, and what third-party testing was done?
  3. What is its regulatory status, and what does the evidence show for the intended use?

Have questions about peptide research?

Talk with our clinical team about your questions, in person or via telemedicine.

Call (561) 214-3323

Referenced Research

1

A laboratory and animal study found that thymosin alpha-1 triggered dendritic cell maturation and interleukin-12 production through toll-like receptor signaling (p38 MAPK and NF-κB pathways). In mice, it was associated with Th1-dependent antifungal immunity and protection of immunocompromised transplant recipients from aspergillosis. These are preclinical findings.

Romani L, Bistoni F, Gaziano R, et al. “Thymosin α1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.” Blood, 2004;103(11):4232–4239.

2

A systematic review and meta-analysis pooled 11 randomized trials (1,927 patients) of thymosin alpha-1 in sepsis. Overall 28-day mortality was lower (OR 0.73; 95% CI 0.59–0.90), but the difference was not seen in high-quality studies (OR 0.82; 95% CI 0.65–1.03) or multicenter trials (OR 0.86; 95% CI 0.68–1.08). The authors noted all studies were conducted in China, publication bias was evident, and the pooled sample size was inadequate.

Gu B, Zhou Y, Nie Y, et al. “Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in Cellular and Infection Microbiology, 2025;15:1673959. doi:10.3389/fcimb.2025.1673959.

3

At its December 4, 2024 meeting, the FDA’s Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on including thymosin alpha-1 (free base) on the 503A bulks list, and the same on thymosin alpha-1 acetate. Members voting no cited the absence of compelling evidence of clinical effectiveness and safety for the uses reviewed.

U.S. Food and Drug Administration. “Final Summary Minutes, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024.” fda.gov/media/185642/download

Important Disclosures

  • This article is for educational purposes only and is not medical advice. These statements have not been evaluated by the U.S. Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure, or prevent any disease.
  • Thymosin alpha-1 is not FDA-approved for any use. Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.
  • The regulatory situation is evolving. The “Our Perspective” section is editorial and does not represent FDA policy.
  • Treatment decisions are made solely by an independent, licensed clinician after an individualized evaluation, and a doctor-patient relationship is established only after a qualifying consultation.

10%

off, especially for you 🎁

Sign up to receive your exclusive discount, and keep up to date on our latest products & services

We don’t spam! Read our privacy policy

Tagged , , , , , , , , , ,